glucagon receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
=== Magnesium sulfate overdose === It is also used to counteract an overdose of Epsom salts magnesium sulfate, which is often administered to pregnant women in order to prophylactically prevent seizures (as in a patient experiencing preeclampsia). Magnesium sulfate is no longer given to pregnant women who are experiencing premature labor in order to slow or stop their contractions (other tocolytics are now used instead due to better efficacy and side effect profiles). Excess magnesium sulfate results in magnesium sulfate toxicity, which results in both respiratory depression and a loss of deep tendon reflexes (hyporeflexia).
== Death == Shortly after midnight on January 19, 2005, Bentley was driving alone when he was killed in a single-car accident in southern California's Ventura County. He was driving on Highway 118 near Simi Valley (30 miles northwest of Los Angeles). Witnesses to the accident stated that Bentley's vehicle was travelling at a high speed towards the Rocky Peak Fire Road off ramp. After running through a stop sign, the vehicle went through a chain-link fence situated across the street and rolled down an embankment. Bentley was ejected from the vehicle into traffic where five cars struck him. He sustained multiple blunt force injuries and was pronounced dead at 12:23 a.m. Bentley was survived by his two daughters and his mother Loyce Bentley. A memorial service for Bentley was held at Forest Lawn Memorial Home in Hollywood Hills, on January 24, 2005. He was buried at Forest Lawn Memorial Park, Hollywood Hills.
King William I appointed Otto von Bismarck as the Minister President of Prussia in 1862. Bismarck successfully concluded the war with Denmark in 1864; the subsequent decisive Prussian victory in the Austro-Prussian War of 1866 enabled him to create the North German Confederation which excluded Austria. After the defeat of France in the Franco-Prussian War, the German princes proclaimed the founding of the German Empire in 1871. Prussia was the dominant constituent state of the new empire; the King of Prussia ruled as its Emperor (Kaiser), and Berlin became its capital. In the Gründerzeit period following the unification of Germany, Bismarck's foreign policy as chancellor of Germany secured Germany's position as a great nation by forging alliances and avoiding war. However, under Wilhelm II, Germany took an imperialistic course, leading to friction with neighbouring countries. A dual alliance was created with the multinational realm of Austria-Hungary; the Triple Alliance of 1882 included Italy. Britain, France and Russia also concluded alliances to protect against Habsburg interference with Russian interests in the Balkans or German interference against France. At the Berlin Conference in 1884, Germany claimed several colonies including German East Africa, German South West Africa, Togoland, and Kamerun. Germany later expanded its colonial empire to include holdings in the Pacific and China.
== External links == Anatomy Atlases – Microscopic Anatomy, plate 07.141 - "Axillary Sweat Gland: Myoepithelium" Histology image: 43_13 at the University of Oklahoma Health Sciences Center - "thick skin" Histology at KUMC glands-glands09 "Simple Tubular Coiled" Costoff, A., Essentials of Human Physiology, archived from the original on 2015-11-20{{citation}}: CS1 maint: bot: original URL status unknown (link)
Sources: en.wikipedia.org
The Dervish movement successfully repulsed the British Empire four times and forced it to retreat to the coastal region. The Darawiish defeated the Italian, British, Abyssinian colonial powers on numerous occasions, most notably, the 1903 victory at Cagaarweyne commanded by Suleiman Aden Galaydh, forcing the British Empire to retreat to the coastal region in the early 1900s. The Dervishes were finally defeated in 1920 by British airpower.
== Contrast with subduction zone island arcs == Hotspot volcanoes are considered to have a fundamentally different origin from island arc volcanoes. The latter form over subduction zones, at converging plate boundaries. When one oceanic plate meets another, the denser plate is forced downward into a deep ocean trench. This plate, as it is subducted, releases water into the base of the over-riding plate, and this water mixes with the rock, thus changing its composition causing some rock to melt and rise. It is this that fuels a chain of volcanoes, such as the Aleutian Islands, near Alaska.
Kopeček, "Refolding Hydrogels Self-Assembled from N-(2-Hydroxypropyl)methacrylamide Graft Copolymers by Antiparallel Coiled-Coil Formation". Biomacromolecules 7, 1187–1195 (2006) J.-G. Shiah, Y. Sun, C.M. Peterson, R.C. Straight, J. Kopeček, "Antitumor Activity of N-(2-Hydroxypropyl)methacrylamide Copolymer-Meso Chlorin e6 and Adriamycin Conjugates in Combination Treatments". Clinical Cancer Research 6, 1008–1015 (2000) T. Minko, P. Kopečková, J. Kopeček, "Efficacy of Chemotherapeutic Action of HPMA Copolymer-Bound Doxorubicin in a Solid Tumor Model of Ovarian Carcinoma". International Journal of Cancer 86, 108–117 (2000) Z.-R. Lu, P. Kopečková, J. Kopeček, "Polymerizable Fab’ Antibody Fragments for Targeting of Anticancer Drugs". Nature Biotechnology 17, 1101–1104 (1999) C. Wang, R.J. Stewart, J. Kopeček, "Hybrid Hydrogels Assembled from Synthetic Polymers and Coiled-Coil Protein Domains". Nature 397, 417–420 (1999) N.L. Krinick, Y. Sun, D. Joyner, J.D. Spikes, R.C. Straight, J. Kopeček, "A Polymeric Drug Delivery System for the Simultaneous Delivery of Drugs Activatable by Enzymes and/or Light". Journal of Biomaterials Science, Polymer Edition 5, 303–324 (1994) R. Duncan, P. Kopečková, J. Strohalm, I.C. Hume, J.B. Lloyd, J. Kopeček, "Anticancer Agents Coupled to N-(2-Hydroxypropyl)methacrylamide Copolymers. 2. Evaluation of Daunomycin Conjugates In Vivo against L1210 Leukaemia". British Journal of Cancer 57, 147–156 (1988) P. Rejmanová, J. Pohl, M. Baudyš, V. Kostka, J. Kopeček, "Polymers Containing Enzymatically Degradable Bonds. 8.
Life expectancy of people with acromegaly is dependent on how early the disease is detected. Life expectancy after the successful treatment of early disease is equal to that of the general population. Acromegaly can often go on for years before diagnosis, resulting in poorer outcome, and it is suggested that the better the growth hormone is controlled, the better the outcome. Upon successful surgical treatment, headaches and visual symptoms tend to resolve. One exception is sleep apnea, which is present in around 70% of cases but does not tend to resolve with successful treatment of growth hormone level. While hypertension is a complication of 40% of cases, it typically responds well to regular regimens of blood pressure medication. Diabetes that occurs with acromegaly is treated with the typical medications, but successful lowering of growth hormone levels often alleviates symptoms of diabetes. Hypogonadism without gonad destruction is reversible with treatment. Acromegaly is associated with a slightly elevated risk of cancer.
The discoverers suggest that the coalescence and differentiation of iron-cored small planets may have occurred 10 million years after a nucleosynthetic event. 107Pd versus 107Ag correlations observed in bodies, which have clearly been melted since the accretion of the Solar System, must reflect the presence of live short-lived nuclides in the early Solar System.
Sources: en.wikipedia.org
In 2006, the US Food and Drug Administration (FDA) approved the use of Exubera, the first inhalable insulin. It was withdrawn from the market by its maker in 2007 due to lack of acceptance. Inhaled insulin claimed to have similar efficacy to injected insulin, both in terms of controlling glucose levels and blood half-life. Currently, inhaled insulin is short-acting and is typically taken before meals; an injection of long-acting insulin at night is often still required. When people were switched from injected to inhaled insulin, no significant difference was observed in HbA1c levels over three months. Accurate dosing was a particular problem, although people showed no significant weight gain or pulmonary function decline over the length of the trial when compared to the baseline. Following its commercial launch in 2005 in the United Kingdom, it was not (as of July 2006) recommended by National Institute for Health and Clinical Excellence for routine use, except in cases where there is "proven injection phobia diagnosed by a psychiatrist or psychologist". In January 2008, the world's largest insulin manufacturer, Novo Nordisk, also announced that the company was discontinuing all further development of the company's own version of inhalable insulin, known as the AERx iDMS inhaled insulin system. Similarly, Eli Lilly and Company ended its efforts to develop its inhaled Air Insulin in March 2008.
It has also been discovered that mRNA secondary structure is important for cell processes such as transcript stability and translation. The general idea is that the functional domains of mRNA fold upon each other, while the start and stop codon regions generally are more relaxed, which could aid in the signaling of initiation and termination in translation. If the oncoming ribosome pauses because of a knot in the RNA, then the polypeptide could potentially have enough time to fold into a non-native structure before the tRNA molecule can add another amino acid. Silent mutations may also affect splicing, or transcriptional control.
=== Protein structure prediction === Protein structure prediction can be used to provide three-dimensional protein structure predictions of whole proteomes. In 2022, a large-scale collaboration between EMBL-EBI and DeepMind provided predicted structures for over 200 million proteins from across the tree of life. Smaller projects have also used protein structure prediction to help map the proteome of individual organisms, for example isoform.io provides coverage of multiple protein isoforms for over 20,000 genes in the human genome.
GHIH (somatostatin) from the periventricular nucleus circulating concentrations of GH and IGF-1 (negative feedback on the pituitary and hypothalamus) Hyperglycemia Glucocorticoids Dihydrotestosterone Phenothiazines In addition to control by endogenous and stimulus processes, a number of foreign compounds (xenobiotics such as drugs and endocrine disruptors) are known to influence GH secretion and function.
Narco News – news site focusing on drug war in Latin America Drug Policy Facts Major Studies of Drugs and Drug Policy Full text of major government commission reports on the drug laws from around the world over the last 100 years Historical Research on the Drug War Full text of numerous full histories of the drug war and thousands of original historical documents Cato Institute Drug Prohibition Research
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.